Estrogen therapy for hereditary haemorrhagic telangiectasia (HHT): Effects of raloxifene, on Endoglin and ALK1 expression in endothelial cells

Thrombosis and Haemostasis

Volumn 103, Issue 3, 2010, Pages 525-534

  Albiñana, Virginia ^a,b   Bernabeu Herrero, Maria E ^a,d   Zarrabeitia, Roberto ^b,c   Bernabeu, Carmelo ^a,b   Botella, Luisa M ^a,b  

^a CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^c HOSPITAL SIERRALLANA   (Spain)

^d SIEMENS AG   (Germany)

Author keywords

ALK1; Endoglin; Epistaxis; HHT; Raloxifene

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 1; ENDOGLIN; MESSENGER RNA; PLACEBO; RALOXIFENE; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CELL SURFACE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; ENDOTHELIUM CELL; EPISTAXIS; ESTROGEN THERAPY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; OSTEOPOROSIS; PATHOGENICITY; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENDU OSLER WEBER DISEASE; TREATMENT OUTCOME; WOUND HEALING;

ACTIVIN RECEPTORS, TYPE II; AGED; ANTIGENS, CD; CELL LINE; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; EPISTAXIS; ESTROGENS; FEMALE; HUMANS; MENOPAUSE; MIDDLE AGED; PROSPECTIVE STUDIES; RALOXIFENE; RECEPTORS, CELL SURFACE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TELANGIECTASIA, HEREDITARY HEMORRHAGIC; TRANSCRIPTION, GENETIC;

EID: 77749246401     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH09-07-0425     Document Type: Article

References (43)

1. Shovlin CL, Letarte M. Hereditary haemorrhagic telangiectasia and pulmonary arteriovenus malformations: issues in clinical management and review of pathogenic mechanisms. Thorax 1999; 54: 714-729.
2. Kjeldsen AD, Vase P, Green A. Hereditary haemorrhagic telangiectasia: a population-based study of prevalence and mortality in Danish patients. J Intern Med 1999; 245: 31-39.
3. Jessurun GA, Kamphuis DJ, van der Zande FH, et al. Cerebral arteriovenous malformations in The Netherlands Antilles. High prevalence of hereditary hemorrhagic telangiectasia-related single and multiple cerebral arteriovenous malformations. Clin Neurol Neurosurg 1993; 95: 193-198.
4. Fernandez-L A, Sanz-Rodriguez F, Zarrabeitia R, et al. Mutation study of Spanish patients with hereditary hemorrhagic telangiectasia and expression analysis of Endoglin and ALK1. Hum Mutat 2006; 27: 295.
5. Fontalba A, Fernandez-L A, García-Alegria E, et al. Mutation study of Spanish patients with hereditary hemorrhagic telangiectasia. BMC Med Genet 2008; 9: 75.
6. McAllister KA, Grogg KM, Johnson DW, et al. Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 1994; 8: 345-351.
7. Johnson DW, Berg JN, Baldwin MA et al. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet 1996; 13: 189-195.
8. Marchuk DA, Gallione CJ, Morrison LA, et al. A locus for cerebral cavernous malformations maps to chromosome 7q in two families. Genomics 1995; 28: 311-314.
9. Cole SG, Begbie ME, Wallace GM, et al. A new locus for hereditary haemorrhagic telangiectasia (HHT3) maps to chromosome 5. J Med Genet 2005; 42: 577-582.
10. Bayrak-Toydemir P, McDonald J, Akarsu N, et al. A fourth locus for hereditary hemorrhagic telangiectasia maps to chromosome 7. Am J Med Genet 2006; 140: 2155-2162.
11. Abdalla SA, Letarte M. Hereditary haemorrhagic telangiectasia: current views on genetics and mechanisms of disease. J Med Genet 2006; 43: 97-110.
12. Plauchu H, de Chadarévian JP, Bideau A, et al. Age-related clinical profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population. Am J Med Genet 1989; 32: 291-297.
13. Pérez del Molino A, Zarrabeitia R, Fernández A. Hereditary hemorrhagic telangiectasia. Med Clin 2005; 124: 583-587.
14. Morales-Angulo C, del Valle-Zapico A. Hereditary hemorrhagic telangiectasia. Otolaryngol Head Neck Surg 1998; 119: 293.
15. Fernandez-L A, Garrido-Martin EM, Sanz-Rodriguez F, et al. Therapeutic action of tranexamic acid in hereditary haemorrhagic telangiectasia (HHT): regulation of ALK-1/endoglin pathway in endothelial cells. Thromb Haemost 2007; 97: 254-262.
16. Morales-Angulo C, Pérez del Molino A, Zarrabeitia R, et al. Treatment of epistaxes in hereditary haemorrhagic telangiectasia (Rendu-Osler-Weber disease) with tranexamic acid. Acta Otorrinolaringol Esp 2007; 58: 129-132.
17. Shovlin CL, Sulaiman NL, Govani FS, et al. Elevated factor VIII in hereditary haemorrhagic telangiectasia (HHT): association with venous thromboembolism. Thromb Haemost 2007; 98: 1031-1039.
18. Ghosh K, Ghosh K. Hereditary haemorrhagic telangiectasia (HHT): negotiating between the Scylla of bleeding and Charybdis of thrombosis. Thromb Haemost 2008; 100: 162-164.
19. Zacharski LR, Dunbar SD, Newsom WA Jr. Haemostatic effects of Tamoxifen in HHT. Thromb Haemost 2001; 85: 371-372.
20. Mosca L, Grady D, Barrett-Connor E, et al. Effect of raloxifene on stroke and venous thromboembolism according to subgroups in postmenopausal women at increased risk of coronary heart disease. Stroke 2009; 40: 147-155.
21. Sadick H, Naim R, Oulmi J, et al. Plasma surgery and topical estriol: effects on the nasal mucosa and long-term results in patients with Osler's disease. Otolaryngol Head Neck Surg 2003; 129: 233-238.
22. Ades EW, Candal FJ, Swerlick RA, et al. HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J Invest Dermatol 1992; 99: 683-690.
23. Azevedo GD, Franco RF, Baggio MS, et al. Procoagulant state after raloxifene therapy in postmenopausal women. Fertil Steril 2005; 84: 1680-1684.
24. Botella LM, Sánchez-Elsner T, Rius C, et al. Identification of a critical Sp1 site within the endoglin promoter and its involvement in the transforming growth factor-beta stimulation. J Biol Chem 2001; 276: 34486-34494.
25. Rius C, Smith JD, Almendro N, et al. Cloning of the promoter region of human endoglin, the target gene for hereditary hemorrhagic telangiectasia type 1. Blood 1998; 92: 4677-4690.
26. Sánchez-Elsner T, Botella LM, Velasco B, et al. Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways. J Biol Chem 2002; 277: 43799-43808.
27. Henry-Berger J, Mouzat K, Baron S, et al. Endoglin (CD105) expression is regulated by the liver X receptor alpha (NR1H3) in human trophoblast cell line JAR. Biol Reprod 2008; 78: 968-975.
28. Botella LM, Sánchez-Elsner T, Sanz-Rodriguez F, et al. Transcriptional activation of endoglin and transforming growth factor-beta signaling components by cooperative interaction between Sp1 and KLF6: their potential role in the response to vascular injury. Blood 2002; 100: 4001-4010.
29. Martino S, Costantino J, McNabb M, et al. The role of selective estrogen receptor modulators in the prevention of breast cancer: comparison of the clinical trials. Oncologist 2004; 9: 116-125.
30. Barettino D, Vivanco Ruiz MM, Stunnenberg HG. Characterization of the ligand-dependent transactivation domain of thyroid hormone receptor. EMBO J 1994; 13: 3039-3049.
31. McDonnell DP, Clemm DL, Hermann T, et al. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol Endocrinol 1995; 9: 659-669.
32. Yang NN, Venugopalan M, Hardikar S, et al. Identification of an estrogen response element activated by metabolites of 17beta-estradiol and raloxifene. Science 1996; 273: 1222-25.
33. Paech K, Webb P, Kuiper GG, et al. Differential ligand activation of estrogen receptors ERa and ERßat AP1 sites. Science 1997; 277: 1508-1510.
34. Webb P, Lopez GN, Uht RM, et al. Tamoxifen activation of the estrogen receptor/ AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol Endocrinol 1995; 9: 443-456.
35. Shang Y, Brown M. Molecular determinants for the tissue specificity of SERMs. Science 2002; 295: 2465-2468.
36. Scafonas A, Reszka AA, Kimmel DB, et al. Agonist-like SERM effects on ERalpha-mediated repression of MMP1 promoter activity predict in vivo effects on bone and uterus. J Steroid Biochem Mol Biol 2008; 110: 197-206.
37. Catalano S, Rizza P, Gu G, et al. Fas ligand expression in TM4 Sertoli cells is enhanced by estradiol "in situ" production. J Cell Physiol 2007; 211: 448-456.
38. Hardman MJ, Emmerson E, Campbell L, et al. Selective estrogen receptor modulators accelerate cutaneous wound healing in ovariectomized female mice. Endocrinology 2008; 149: 551-557.
39. Li DY, Sorensen LK, Brooke BS, et al. Defective angiogenesis in mice lacking endoglin. Science 1999; 284: 1534-1537.
40. Fonsatti E, Altomonte M, Nicotra MR, et al. Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels. Oncogene 2003; 22: 6557-6563.
41. Lebrin F, Deckers M, Bertolino P, et al. TGF-beta receptor function in the endothelium. Cardiovasc Res 2005; 65: 599-608.
42. Adomaityte J, Farooq M, Qayyum R. Effect of raloxifene therapy on venous thromboembolism in postmenopausal women: A meta-analysis. Thromb Haemost 2008; 99: 338-342.
43. Eilertsen AL, Liestøl S, Mowinckel MC, et al. Differential impact of conventional and low-dose oral hormone therapy (HT), tibolone and raloxifene on functionality of the activated protein C system. Thromb Haemost 2007; 97: 938-943.